Cambridge, MA-based Forma Therapeutics has struck a collaboration deal with the U.S. unit of Tokyo-based drug powerhouse Eisai that is focused on discovering drugs against normally intractable disease targets, according to the companies. Eisai is paying Forma $20 million in upfront and committed fees over a three-year period, according to the companies. The deal gives Eisai non-exclusive access to Forma’s proprietary compound library and cell-based screening platforms to aid in Eisai’s discovery of new drugs for its own pipeline. Forma is eligible for potential milestone payments and royalties on products that Eisai might decide to develop as a result of the collaboration.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
